General Information:

Id: 942
Diseases: Parkinson disease
Synucleinopathy
Homo sapiens
BTO:0000793 SH-SY5Y cell
article
Reference: Gerard M et al.(2010) Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinsons disease-like pathology. J. Neurosci. 30: 2454-2463 [PMID: 20164329]

Interaction Information:

Comment In stable alpha-SYN-overexpressing SHSY5Y cells, the number of cells with alpha-SYN inclusions is increased after oxidative stress.
Formal Description
Interaction-ID: 5715

increases_quantity of

Comment FK506 reduces alpha-SYN aggregation and apoptosis in the synucleinopathy model.
Formal Description
Interaction-ID: 5716

drug/chemical compound

Tacrolimus

decreases_quantity of

Drugbank entries Show/Hide entries for Tacrolimus
Comment FK506 reduces alpha-SYN aggregation and apoptosis in the synucleinopathy model.
Formal Description
Interaction-ID: 5717

drug/chemical compound

Tacrolimus

decreases_activity of

Drugbank entries Show/Hide entries for Tacrolimus
Comment Overexpression of FKBP12 and FKBP52 enhances alpha-SYN aggregation and apoptosis in a cellular model for synucleinopathy.
Formal Description
Interaction-ID: 5718

gene/protein

FKBP1A

increases_quantity of

Drugbank entries Show/Hide entries for FKBP1A
Comment Overexpression of FKBP12 and FKBP52 enhances alpha-SYN aggregation and apoptosis in a cellular model for synucleinopathy.
Formal Description
Interaction-ID: 5719

gene/protein

FKBP4

increases_quantity of